Shoker Investment Counsel’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-10,174
| Closed | -$2.84M | – | 112 |
|
|
2025
Q2 | $2.84M | Sell |
10,174
-334
| -3% | -$94.6K | 0.89% | 34 |
|
|
2025
Q1 | $3.27M | Buy |
10,508
+324
| +3% | +$95.7K | 1.11% | 26 |
|
|
2024
Q4 | $2.65M | Buy |
10,184
+116
| +1% | +$34.4K | 0.9% | 37 |
|
|
2024
Q3 | $3.24M | Sell |
10,068
-357
| -3% | -$117K | 1.09% | 28 |
|
|
2024
Q2 | $3.26M | Sell |
10,425
-94
| -0.9% | -$27.6K | 1.15% | 27 |
|
|
2024
Q1 | $2.98M | Buy |
10,519
+74
| +0.7% | +$21.7K | 1.06% | 27 |
|
|
2023
Q4 | $3.01M | Buy |
10,445
+20
| +0.2% | +$5.45K | 1.16% | 25 |
|
|
2023
Q3 | $2.8M | Sell |
10,425
-78
| -0.7% | -$19.5K | 1.22% | 24 |
|
|
2023
Q2 | $2.33M | Buy |
10,503
+15
| +0.1% | +$3.48K | 0.97% | 34 |
|
|
2023
Q1 | $2.54M | Sell |
10,488
-107
| -1% | -$26.3K | 1.11% | 30 |
|
|
2022
Q4 | $2.78M | Buy |
10,595
+103
| +1% | +$27.6K | 1.25% | 24 |
|
|
2022
Q3 | $2.36M | Buy |
10,492
+418
| +4% | +$101K | 1.24% | 27 |
|
|
2022
Q2 | $2.45M | Buy |
10,074
+322
| +3% | +$78.9K | 1.3% | 29 |
|
|
2022
Q1 | $2.36M | Buy |
9,752
+65
| +0.7% | +$14.9K | 1.17% | 28 |
|
|
2021
Q4 | $2.18M | Sell |
9,687
-9
| -0.1% | -$1.9K | 1% | 33 |
|
|
2021
Q3 | $2.06M | Buy |
9,696
+43
| +0.4% | +$9.9K | 1.03% | 32 |
|
|
2021
Q2 | $2.35M | Buy |
9,653
+124
| +1% | +$30.5K | 1.17% | 25 |
|
|
2021
Q1 | $2.37M | Sell |
9,529
-184
| -2% | -$43.9K | 1.24% | 22 |
|
|
2020
Q4 | $2.23M | Buy |
9,713
+43
| +0.4% | +$9.91K | 1.25% | 24 |
|
|
2020
Q3 | $2.46M | Buy |
9,670
+43
| +0.4% | +$10.7K | 1.61% | 17 |
|
|
2020
Q2 | $2.27M | Sell |
9,627
-190
| -2% | -$43.4K | 1.58% | 17 |
|
|
2020
Q1 | $1.99M | Buy |
9,817
+493
| +5% | +$108K | 1.68% | 18 |
|
|
2019
Q4 | $2.25M | Buy |
9,324
+87
| +0.9% | +$19.2K | 1.49% | 18 |
|
|
2019
Q3 | $1.79M | Buy |
9,237
+103
| +1% | +$19.8K | 1.28% | 26 |
|
|
2019
Q2 | $1.68M | Sell |
9,134
-48
| -0.5% | -$8.6K | 1.23% | 29 |
|
|
2019
Q1 | $1.74M | Buy |
9,182
+15
| +0.2% | +$2.87K | 1.29% | 26 |
|
|
2018
Q4 | $1.78M | Buy |
9,167
+107
| +1% | +$20.9K | 1.5% | 19 |
|
|
2018
Q3 | $1.88M | Sell |
9,060
-57
| -0.6% | -$11.2K | 1.36% | 19 |
|
|
2018
Q2 | $1.68M | Sell |
9,117
-71
| -0.8% | -$12.6K | 1.25% | 20 |
|
|
2018
Q1 | $1.57M | Sell |
9,188
-85
| -0.9% | -$15.6K | 1.19% | 21 |
|
|
2017
Q4 | $1.61M | Sell |
9,273
-228
| -2% | -$40.4K | 1.16% | 24 |
|
|
2017
Q3 | $1.77M | Sell |
9,501
-442
| -4% | -$78.3K | 1.34% | 22 |
|
|
2017
Q2 | $1.71M | Buy |
9,943
+278
| +3% | +$45.2K | 1.35% | 20 |
|
|
2017
Q1 | $1.58M | Sell |
9,665
-280
| -3% | -$46.5K | 1.33% | 23 |
|
|
2016
Q4 | $1.45M | Buy |
9,945
+4,329
| +77% | +$652K | 1.2% | 25 |
|
|
2016
Q3 | $936K | Buy |
5,616
+71
| +1% | +$12K | 0.79% | 41 |
|
|
2016
Q2 | $843K | Buy |
5,545
+449
| +9% | +$69.8K | 0.75% | 43 |
|
|
2016
Q1 | $764K | Buy |
5,096
+1,191
| +30% | +$177K | 0.72% | 42 |
|
|
2015
Q4 | $633K | Buy |
3,905
+1,089
| +39% | +$171K | 0.63% | 46 |
|
|
2015
Q3 | $389K | Buy |
+2,816
| New | +$444K | 0.41% | 61 |
|
Other funds holding AMGN
Shoker Investment Counsel's AMGN Position: Q3 2025 in Review
Shoker Investment Counsel sold out of Amgen (AMGN) in Q3 2025, closing a stake of 10,174 shares — an estimated $2.84M sold.
Shoker Investment Counsel first reported a position in AMGN in Q3 2015 and held it in 40 quarters. The position peaked at $3.27M in Q1 2025. 2,819 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.
- Shoker Investment Counsel reported no remaining Amgen position as of Q3 2025 after selling out during the quarter.
- Shoker Investment Counsel sold 10,174 Amgen shares in Q3 2025, an estimated $2.84M.
- Shoker Investment Counsel first reported a position in Amgen in Q3 2015 and held it in 40 quarters.
- Shoker Investment Counsel's Amgen position peaked at $3.27M in Q1 2025.
- 2,819 funds tracked by Wall St. Rank held Amgen as of Q3 2025.
Based on Shoker Investment Counsel's 13F filing for Q3 2025, filed 31 Oct 2025.